Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients
Authors:
- Irene T. SchrijverIrene T. Schrijver
- Jacobus HerderscheeJacobus Herderschee
- Charlotte ThéroudeCharlotte Théroude
- Antonios KritikosAntonios Kritikos
- Guus LeijteGuus Leijte
- Didier Le RoyDidier Le Roy
- Maelick BrochutMaelick Brochut
- Jean-Daniel ChicheJean-Daniel Chiche
- Matthieu PerreauMatthieu Perreau
- Giuseppe PantaleoGiuseppe Pantaleo
- Benoit GueryBenoit Guery
- Matthijs KoxMatthijs Kox
Open Access
Abstract
Patients admitted to the intensive care unit (ICU) often experience endotoxemia, nosocomial infections and sepsis. Polymorphonuclear and monocytic myeloid-derived suppressor cells (PMN-MDSCs and M-MDSCs) can have an important impact on the development of infectious diseases, but little is known about their potential predictive value in critically ill patients. Here, we used unsupervised flow cytometry analyses to quantify MDSC-like cells in healthy subjects challenged with endotoxin and in critically ill patients admitted to intensive care units and at risk of developing infections. Cells phenotypically similar to PMN-MDSCs and M-MDSCs increased after endotoxin challenge. Similar cells were elevated in patients at ICU admission and normalized at ICU discharge. A subpopulation of M-MDSC-like cells expressing intermediate levels of CD15 (CD15int M-MDSCs) was associated with overall mortality (p = 0.02). Interestingly, the high abundance of PMN-MDSCs and CD15int M-MDSCs was a good predictor of mortality (p = 0.0046 and 0.014), with area under the ROC curve for mortality of 0.70 (95% CI = 0.4–1.0) and 0.86 (0.62–1.0), respectively. Overall, our observations support the idea that MDSCs represent biomarkers for sepsis and that flow cytometry monitoring of MDSCs may be used to risk-stratify ICU patients for targeted therapy.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_207418, 676129, 847422)
- Fondation Carigest/Promex Stiftung für die Forschung (Geneva, Switzerland) (310030_207418, 676129, 847422)
- European Commission (310030_207418, 676129, 847422)
- European Commission (310030_207418, 676129, 847422)
- Société Académique Vaudoise (Lausanne, Switzerland) (310030_207418, 676129, 847422)
This publication has 56 references indexed in Scilit:
- STAT4 knockout protects LPS-induced lung injury by increasing of MDSC and promoting of macrophage differentiationRespiratory Physiology & Neurobiology, 2016
- Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patientsClinical and Experimental Immunology, 2015
- A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive casesJournal of Leukocyte Biology, 2014
- Epigenetics in sepsis: targeting histone deacetylasesInternational Journal of Antimicrobial Agents, 2013
- Bench-to-bedside review: Clinical experience with the endotoxin activity assayCritical Care, 2012
- Myeloid-Derived Suppressor Cells Evolve during Sepsis and Can Enhance or Attenuate the Systemic Inflammatory ResponseInfection and Immunity, 2012
- Myeloid-derived suppressor cells control microbial sepsisIntensive Care Medicine, 2012
- Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia*Critical Care Medicine, 2011
- The Terminology Issue for Myeloid-Derived Suppressor CellsCancer Research, 2007
- Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometryCytometry Part B: Clinical Cytometry, 2004